It’s a big day for Apricus Biosciences (NASDAQ:APRI). The drug maker announced this morning its execution of a definitive agreement to merge with Seelos Therapeutics, …
Did an iceberg just wallop into Apricus Biosciences (NASDAQ:APRI) stock? The biotech company’s shares are plunging at breakneck speed of almost 15%.
Roth Capital analyst Scott Henry reiterated a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a $4 price target, following the company’s third quarter results, which were within …
In a research report released Wednesday, Cantor analyst Irina Rivkind maintained a Hold rating on Apricus Biosciences (NASDAQ:APRI) with a price target of $1.50, …
In a research report issued today, Cantor analyst Irina Rivkind maintained a Hold rating on Apricus Biosciences (NASDAQ:APRI) and reduces her price target to $1.50 …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a price target of $4.00, …
